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Wolf-Dietrich Huber, MD,d and Rudolf Valenta, MDa Vienna, Austria, and Erlangen, GermanyBackground: Celiac disease (CD) is an inflammatory disease of
the small intestine caused by an immunologic hypersensitivity
reaction to dietary wheat gluten.
Objectives: We sought to clone, express, and perform IgA
epitope mapping of a CD-specific wheat antigen and to study its
usefulness for identifying patients with CD and monitoring
adherence to a gluten-free diet.
Methods: A synthetic gene coding for g-gliadin 1 (GG1) was
expressed in Escherichia coli. Recombinant g-gliadin 1 (rGG1)
was purified and characterized biochemically, structurally, and
immunologically by using sera from patients with CD and
control subjects. Overlapping GG1 peptides were synthesized
for IgA and IgG epitope mapping. GG1 and peptide-specific
antibodies were raised for tracing GG1 in cereals and dietary
wheat products and to study its resistance to digestion.
Results: rGG1 was expressed and purified. rGG1-based IgA
ELISAs performed in populations of patients with CD and
control subjects showed a specificity of 92.9%, which was higher
than that of gliadin extract (e). Furthermore, it allowed
monitoring of adherence to a gluten-free diet in patients.
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http://dx.doi.org/10.1016/j.jaci.2015.04.040repetitive N-terminal region was identified as the
immunodominant IgA epitope. GG1-related antigens were
found in rye, barley, and spelt but not in oat, rice, or maize.
GG1 was detected in dietary wheat products after baking, and
in particular, the major IgA epitope–containing region was
resistant against digestion.
Conclusions: rGG1 and its epitope might be useful for identifying
patients with CD, monitoring treatment, and studying the
pathomechanisms of CD and development of preventive and
therapeutic strategies. (J Allergy Clin Immunol 2015;136:1607-18.)
Key words: Celiac disease, cloning, recombinant gamma gliadin 1,
epitope
Celiac disease (CD) is an inflammatory disease of the small
intestine caused by a hypersensitive immune response to dietary
gluten proteins that affects 0.7% to 2% of the European and
American population.1,2 CD is characterized by small intestinal
villous atrophy, crypt hyperplasia, and infiltration of gliadin-
specific lymphocytes in the lamina propria.3 On gluten exposure,
patients usually secrete high titers of anti-gliadin antibodies
(AGAs) and antibodies against endomysial proteins (EMA)
proteins.4 Tissue transglutaminase 2 (tTG2) was identified as
one of the endomysial autoantigens.5 Interestingly, deamidation
of gliadin peptides by tTG2 enhances activation and IFN-g
secretion by gliadin-specific T cells, which is thought to lead to
mucosal damage.6 Assays measuring levels of anti-tTG2 and
anti-deamidated gliadin peptide (DGP) antibodies are being
used for the diagnosis of CD. Although these tests are very useful
for diagnosis, they are not ideally suited for the monitoring of a
patient’s adherence to a gluten-free diet (GFD).7 Measurement
of AGA levels for diagnosis is less frequently performed because
of their lower specificity and sensitivity.8
In fact, AGA tests are based on an alcohol-soluble fraction of
wheat, termed the gliadin fraction, which is a complex mixture of
water-insoluble seed storage proteins. Within the gliadin fraction,
many proteins can be found, among them cysteine-rich
a/b-gliadins, g-gliadins, and cysteine-poor v-gliadins, which
occur in numerous isoforms and heterogeneities, all of which
might not be equally toxic to patients with CD.9-11
We have recently developed a subfractionation technique for
the gliadin fraction to enrich highly CD-specific IgA-reactive
antigens. Analysis of the subfractions for IgA reactivity with sera
from patients with CD and control subjects revealed that the
subfraction containing a/b-gliadins had lower specificity than a
subfraction that was rich in g-gliadins. Within this CD-specific
IgA-reactive fraction, we identified peptide sequences derived
from g-gliadins as possible CD-specific IgA-reactive wheat
antigens based on mass spectrometry and protein sequencing.121607
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flightNCBI: National Center for Biotechnology InformationPBST: PBS with 0.05% Tween 20rGG1: Recombinant g-gliadin 1tTG2: Tissue transglutaminase 2The aim of this study was the molecular characterization,
cloning, and epitope mapping of a CD-specific wheat antigen. We
also sought to study its usefulness for identifying patients with
CD and monitoring adherence to a GFD. Based on the previously
obtained g-gliadin peptide sequences, we have now constructed a
synthetic gene coding for a g-gliadin, which we designated
g-gliadin 1 (GG1), expressed the recombinant protein in
Escherichia coli, purified it to homogeneity and performed a
biochemical and structural analysis of the recombinant protein.
The recombinant protein was then evaluated for specific IgA
reactivity with sera from patients with CD and various control
populations. Furthermore, we studied the usefulness of IgA
anti–recombinant g-gliadin 1 (rGG1) antibodies for monitoring
adherence to GFD. IgA epitopes were mapped by testing a series
of overlapping synthetic peptides. Rabbit antisera were raised
against the recombinant protein and its major IgA-reactive
peptide to identify related antigens in other cereals and to
investigate its resistance to baking and digestion.METHODS
Identification of GG1 based on amino acid sequence
data, cloning, and expression of rGG1
Using a combined biochemical and immunologic approach, we have
identified a subfraction of wheat gliadin that reacted specifically to IgA
antibodies from patients with CD.12 Within this subfraction, 2 peptide
sequences (ie, N-terminus: NIQVDPSGQ; internal peptide, APFASIVA-
GIGGQ) belonging to g-gliadins were obtained from the approximately
35-kDa protein band. When we searched the SwissProt database for wheat
sequences coding for proteins of the corresponding molecular weight
containing both peptides, we identified GG1 from Triticum aestivum
(SwissProt accession no. P08453.1) as a candidate antigen. A National Center
for Biotechnology Information (NCBI) Protein blast (http://blast.ncbi.nlm.
nih.gov) of the amino acid sequence of GG1 with sequences from T aestivum
(taxid:4565) deposited in the NCBI nonredundant protein sequences (nr)
database yielded 25 g-gliadin isoforms of similar molecular weights
containing both peptides, which differed only in a few amino acids.
A synthetic gene containing the sequence coding for the mature protein of
the GG1 gene (GenBank: M16064, SwissProt ID: P08453.1) along with a
C-terminal 6x Histidine tag and methionine as a start codon, which was codon
optimized for expression in E coli, was obtained from GenScript (Piscataway
Township, NJ) and cloned into pET-27b(1) (Novagen, Darmstadt, Germany).
The pET-GG1 construct was transformed into E coli BL21 (DE3;
Invitrogen, Carlsbad, Calif), and rGG1 was expressed in liquid cultures and
purified, as previously described.13Multiple sequence alignment of GG1 with
homologous proteins from other cereals
An NCBI Protein blast (http://blast.ncbi.nlm.nih.gov) search of GG1
(SwissProt ID: P08453.1) against spelt (Triticum spelta), rye (Secale cereale),
barley (Hordeum vulgare L), maize (Zea mays), rice (Oryza sativa), and oat
(Avena sativa)was performed. A protein sequence showingmaximum identity
with GG1 from each of the cereals was chosen for multiple sequence align-
ment by using Clustal Omega software from the EMBL-EBI Web site
(http://www.ebi.ac.uk/Tools/msa/clustalo/).14
Protein extracts and SDS-PAGE
Gliadin extract (e) from Taestivumwas prepared according to the Osborne
protocol.15 Seed extracts from wheat, rye, spelt, barley, maize, oat, and rice
and protein extracts of crust and crumbs of 3 types of commonly consumed
breads were prepared for immunoblotting, as previously described.13
Migration patterns of extracts and rGG1 under reducing and nonreducing
conditions were compared by mixing 10 mg of rGG1 with Laemmli sample
buffer containing b-mercaptoethanol (reducing) or without b-mercaptoetha-
nol (nonreducing) by using 12% SDS-PAGE and staining of gels with
Coomassie Brilliant Blue R-250.12
Matrix-assisted laser desorption and ionization-time-of-flight (MALDI-
TOF) mass spectrometry of rGG1 was performed in a positive linear mode by
using MALDI-TOF with the Compact MALDI II instrument (Kratos, Man-
chester, United Kingdom; piCHEM, R&D, Graz, Austria).Circular dichroism analysis of purified rGG1
The rGG1 protein was dialyzed in 40 mmol/L acetic acid, and the circular
dichroism spectra of rGG1 were analyzed by using a Jasco J-810 Spectropo-
larimeter (JASCO, Tokyo, Japan). The far-UV circular dichroism spectra from
190 to 260 nm were recorded in a 2-mm path length quartz cuvette (Hellma,
Mullheim, Baden, Germany) with a resolution of 1 nm, a scan speed of 50 nm/
min, and a protein concentration of 0.10 mg/mL, and an average of 3 scans
were obtained. Measurements were taken at 218C. Results are expressed as
mean residue ellipticity (degrees per square centimeter per decimole)3 103 at
a given wavelength. Secondary structure analysis was performed with the
CDSSTR algorithm from DICHROWEB.Sera from patients with CD and control subjects
Sera were taken from 63 untreated patients with CD (median age, 26 years;
range, 0.4-65 years; male/female sex, 16/49) who received a diagnosis
according to European Society for Paediatric Gastroenterology, Hepatology
and Nutrition guidelines.16 All the patients had positive test results regarding
EMA, for IgA reactivity to tTG2 QUANTA Lite ELISA diagnostic kits (Inova
Diagnostics, San Diego, Calif) and for the presence of either IgA, IgG, or both
against deamidated gliadin (DGP) QUANTA Lite ELISA diagnostic kits
(Inova Diagnostics). Additional serum samples were obtained from 6 patients
(median age, 8 years; range, 1-10 years; male/female sex, 0/6) before and after
GFD (GFD: 6 months to 81 months) and from 18 patients with CD who
had received GFD for a period of 4 months up to 7 years (median age, 8 years;
range, 1-69 years; male/female sex, 4/14). The AGA1/EMA2 subjects
(n 5 13; median age, 1 year; range, 0.5-14 years; male/female sex, 9/4) had
negative results regarding EMA. In this group 13 of 13 subjects also had
negative test results for IgA against tTG2, 11 of 13 had negative results for
IgA against DGP, and 9 of 13 had negative results for IgG against DGP. For
control purposes, sera from 55 patients with intestinal disorders (IDs; eg,
Crohn disease [n5 26;median age, 38 years; range, 0.4-75 years; male/female
sex, 10/16] and ulcerative colitis [n5 22;median age, 32.5 years; range, 21-76
years; male/female sex, 14/8]) or intestinal adenocarcinoma, colon cancer, or
polyps (n 5 7; median age, 59 years; range, 47-77 years; male/female sex,
4/3); sera from 32 allergic subjects (wheat food allergy: n 5 7; median age,
39 years; range, 36-49 years; male/female sex, 2/3; information on 2 patients
was not available), patients with baker’s asthma (n5 6; median age, 37 years;
range, 12-45 years; male/female sex, 5/1), patients with milk allergy (n5 13;
median age, 24 years; range, 1-64 years; male/female sex, 4/9), or patients
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male/female sex, 5/1); and sera from 41 healthy volunteers were tested.
Subjects from the control groups had negative test results for CD by using
the diagnostic test kits mentioned above. Sera were obtained in the course
of routine diagnostic procedures, and residual serum samples were tested in
an anonymized and retrospective manner with permission from the Ethical
Committee of the Medical University of Vienna.rGG1-derived synthetic peptides
For IgA and IgG epitope mapping, 19 overlapping peptides with lengths of
between 18 to 26 amino acids spanning the length of rGG1 were synthesized
and purified, as previously described.17IgA reactivity to rGG1 and gliadin extract (e) and
epitope mapping using synthetic overlapping
peptides by means of ELISA
ELISA plates (Maxisorp; Nunc, Roskilde, Denmark) were either coated
with gliadin extract (e) or rGG1. For peptidemapping, plates were coated with
rGG1 or rGG1-derived synthetic peptides. The antigens were coated at a
concentration of 5 mg/mL diluted in bicarbonate buffer (pH 9.0) overnight at
48C and washed twice with PBS with 0.05% Tween 20 (PBST). The plates
were then blocked with 1%BSA in PBST for 2 hours at room temperature and
incubated overnight at 48C with human sera diluted 1:100 and 1:1000 for IgA
and IgG binding, respectively, or with buffer alone. The plates were washed
with PBST and incubated with an anti-human IgA1/IgA2 mAb (BD Biosci-
ences, San Jose, Calif) at 1:1000 dilution or a monoclonal anti-human IgG
(BD Biosciences) at 1:1000 for 5 hours at 48C. After washing, the bound
antibodies were detected by incubating the plates with 1:1000 diluted sheep
anti-mouse horseradish peroxidase–conjugated antibodies (GE Healthcare,
Buckinghamshire, UnitedKingdom). Results representmeans of duplicate de-
terminations with less than 2% variation.Production of rabbit antibodies specific for rGG1
and peptides 4 and 18
Antibodies specific for rGG1 were obtained by means of immunization of
rabbits, as previously described.12 Antibodies to rGG1-derived peptide 4 and
peptide 18 were obtained by coupling the peptides to keyhole limpet hemocy-
anin by using Imject EDC mcKLH Spin Kit (Thermo Fisher Scientific, Rock-
ford, Ill) before immunization.In vitro digestion of rGG1, simulating gastric and
duodenal digestion
In vitro digestion of rGG1 was performed by using 2 enzymes: first diges-
tion with pepsin and then chymotrypsin.18,19 Briefly, rGG1 solubilized in 50
mmol/L acetic acid was digested first with 1:100 wt/wt pepsin. The peptic
digestion was carried out at 378C, and aliquots of digested samples were
collected at 15, 30, 60, 90, and 120 minutes. The reaction was stopped by
increasing the pH of the samples up to 8.0 by addition of 1 mol/L NaOH.
The peptic digest was then further digested with 1:100 wt/wt chymotrypsin
in a solution containing 100 mmol/L Tris and 10 mmol/L CaCl2 (pH 8.3).
The reaction mixture was incubated at 378C, and aliquots were collected at
15, 30, 60, 90, 120, and 240 minutes and 20 hours. The reaction was stopped
by heating the samples to 958C for 5 minutes.
According to pilot SDS-PAGE stained with Coomassie blue, comparable
amounts of cereal extracts, bread crumbs, and crust extracts were separated by
means of SDS-PAGE20 and blotted onto nitrocellulose.21 GG1 moieties were
detected with specific rabbit antibodies.12Statistics
Data were analyzed by using GraphPad Prism statistical software
(GraphPad Software, San Diego, Calif). The receiver operating characteristiccurve was plotted, and the AUC and Youden index (J)22 were calculated and
used to determine the best cutoff value for anti-rGG1 and anti-gliadin extract
(e) antibodies. Statistical significance between 2 groupswas analyzed by using
the Mann-Whitney U test and Wilcoxon matched-pairs test.RESULTS
Domain architecture of wheat GG1, which was
produced as recombinant antigen
We have previously identified 2 peptide sequences of wheat
g-gliadin in a subfraction of wheat gliadin that showed highly
specific IgA reactivity in sera from patients with CD.12 Based
on sequence comparisons, we identified a corresponding
wheat GG1 protein in the database (SwissProt accession
no. P08453.1, see Fig E1 in this article’s Online Repository
at www.jacionline.org). This protein has also been
described to contain a T-cell epitope (ie, 134-153:
QQLPQPQQPQQSFPQQQRPF) recognized by a T-cell clone
isolated from the gut of a patient with CD (Fig 1, light blue
box).23,24 The architecture of the corresponding GG1 precursor
protein is shown in Fig E1, A. The precursor protein comprises
327 amino acids, of which the 19 N-terminal amino acids are
cleaved to yield the mature protein containing 308 amino acids.
GG1 contains high amounts of Gln (35.4%) and Pro (17.5%),
as is typical for g-gliadins.25 GG1 can be grouped into 5 do-
mains (see Fig E1, A).26 Domain I is a short N-terminal non-
repetitive region, whereas domain II represents the Pro- and
Gln-rich repetitive region. In closely related g-gliadins from
wheat, the characteristic PQQPFPQ repeat occurs 8 times and
the PQQPFPQQPQQPFPQTQQ sequence occurs 3 times in
this domain, and the domain is usually devoid of negatively
charged amino acids. GG1 domain III is a cysteine-rich region
with 5 cysteine residues. Domain IV is rich in glutamine, and
domain V is a C-terminal nonrepetitive region, which, in the
case of GG1, contains 2 cysteine residues.Wheat GG1 has highest sequence homology with
spelt, rye, and barley prolamins
A comparison of the amino acid sequence of the GG1
precursor protein with the sequences deposited in the sequence
databases revealed that it shared significant sequence homology
(>49% sequence identity) with cereal prolamins from spelt, rye,
and barley, whereas sequence homology with prolamins from
oat and rice was much lower (<42% sequence identity, Fig 1).
The spelt protein (GenBank Accession no. AAD30440.1)
showed a sequence identity of 79.2%, the rye protein
(ADP95484.1) showed a sequence identity of 68%, and the
barley protein (ABH01262.1) showed a sequence identity of
49.6%. Prolamins from oat (CCH22519.1) and rice
(ABU89796.1) showed sequence identities of 42.2% and
32.6%, respectively. No proteins with relevant sequence identity
were identified for maize in the databases searched. Sequence
identities were low within the Pro- and Gln-rich domain,
whereas homology was higher in domains III and IV. Further-
more, there was a considerable variation in length and compo-
sition in domains II and IV among the compared proteins.
Domains III and V showed similar length among the various
prolamins. The 7 cysteine residues of GG1 located in domains
III and V (Fig 1, boxed in red) were highly conserved among
FIG 1. Multiple sequence alignment of the GG1 amino acid sequence with amino acid sequences of
prolamins from closely related cereals (spelt, rye, and barley) and distantly related rice and oat. Identical
amino acids are represented by dots, and gaps are represented by dashes. The coloring of the amino acids
is based on the domain architecture, as described in Fig E1, A. The open green and dark blue rectangles
represent peptides 4 and 18, respectively. The T-cell epitope described by Molberg et al24 has been boxed
in light blue. The conserved cysteines are represented by open red rectangles. Percentages of sequence
identities between GG1 and respective prolamins are indicated in bold italics in the bottom right corner.
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barley, for which 2 were missing.rGG1 can be expressed in E coli and purified to
homogeneity
Coomassie-stained SDS-PAGE performed under reducing and
nonreducing conditions showed that the majority of rGG1
migrated at approximately 36 kDa under reducing conditions,
whereas under nonreducing conditions, the protein formed
dimers, tetramers, and higher molecular weight aggregates
(Fig 2, A). The MALDI-TOF analysis of the purified protein
(see Fig E2 in this article’s Online Repository at www.
jacionline.org) shows that the molecular mass of rGG1 is
36,084.9 Da, which fits well with the molecular mass of
36,105.7 Da calculated from its amino acid sequence including
the initial methionine. A second small peak corresponding to amass of 72032.1 Da was observed in the mass spectrum, which
would fit with the dimeric form of the protein, as observed in
SDS-PAGE (Fig 2, A).Structural characterization of rGG1 by means of
circular dichroism spectrometry shows that the
protein is not folded
Analysis of the secondary structure of rGG1 by means of
circular dichroism (Fig 2, B) and subsequent calculation of
the contents of secondary structure with CDSSTR software
showed that the protein was largely unordered, with an
alpha-helix content of less than 25%. No difference was
observed when the circular dichroism spectra were recorded
with rGG1 in 70% ethanol or in 1025 mol/L HCl solutions
(data not shown).
FIG 2. Biochemical and structural characterization of rGG1. A, Coomassie-stained SDS-PAGE containing
rGG1 separated under reducing (left lane) and nonreducing conditions (right lane). Molecular weight
markers (in kilodaltons) are indicated on the left margin. B, Circular dichroism analysis of purified rGG1.
The spectra are expressed as mean residue ellipticities (y-axis) at given wavelengths (x-axis).
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To investigate whether native gliadin-based AGA tests can be
improved by using rGG1, we tested serum IgA reactivity of
patients with active CD, patients with IDs, healthy subjects,
patients with IgE-associated allergies (including food allergy),
and AGA1/EMA2 subjects to rGG1 and gliadin extract (e) (Fig 3,
A). When IgA reactivity to rGG1 was analyzed, 46 of 63 patients
with CD, 1 of 55 patients with IDs, 4 of 41 healthy subjects, 2 of
32 allergic patients, and 3 of 13 AGA1/EMA2 subjects had pos-
itive test results (Fig 3,A). Testing IgA reactivity to gliadin extract
(e) showed that 56 of 63 patients with CD, 5 of 55 patients with
IDs, 7 of 41 healthy subjects, 9 of 32 allergic patients, and 13
of 13 AGA1/EMA2 subjects had positive results (Fig 3, A). In
the CD group the number of patients with positive IgA reactivity
to gliadin extract (e) was higher than the number of patients with
positive IgA reactivity to the rGG1 protein, but in each of the con-
trol groups, the number of patients showing false-positive IgA
reactivity to rGG1 was lower than the number of patients showing
false-positive IgA reactivity to gliadin extract (e). The difference
in IgA reactivity of patients with CD to rGG1 and gliadin extract
(e) was not significant (P 5 .1078; 95.05% CI, 20.0290 to
0.2570), whereas the differences in IgA reactivity of patients
with IDs, healthy subjects, patients with IgE-associated allergies,
and AGA1/EMA2 subjects to rGG1 and gliadin extract (e) were
significant (P 5 .0002 [95.05% CI, 0.0200-0.0500], P 5 .0193
[95.02% CI, 0.0100-0.0800], P 5 .0002 [95.15% CI, 0.0400-
0.1300], and P <.0001 [95.01% CI, 0.3400-1.410], respectively).
Importantly, the receiver operating characteristic AUC for rGG1
(AUC, 0.9314; 95% CI, 0.8740-0.9529; SE, 0.02; P < .0001)
was larger than that for gliadin extract (e) (AUC, 0.8828; 95%CI, 0.8375-0.9281; SE, 0.02; P < .0001; Fig 3, B). The use of
rGG1 in an ELISA-based serum IgA pilot test thus provided a
sensitivity of 73.01% (95% CI, 0.60-0.83) and a specificity of
92.9% (95% CI, 0.87-0.96), whereas gliadin extract (e) had a
sensitivity of 88.8% (95% CI, 0.78-0.95) and a specificity of
75.8% (95% CI, 0.67-0.82). The positive predictive values for
rGG1 and gliadin extract (e) were 82.14% and 62.2%, respec-
tively, and the negative predictive values for rGG1 and gliadin
extract (e) were 88.5% and 93.8%, respectively.IgA against rGG1 for monitoring adherence to a
GFD
In another pilot study we compared antibody levels against
rGG1, tTG2, and DGP in sera obtained from patients with CD
before and after a GFD using longitudinal testing. Serum samples
taken before a GFD were positive in each of the tests, showing
comparable sensitivity of the tests in the tested patients (Fig 4, A).
After a GFD, antibody titers decreased significantly against the
tested proteins (rGG1: P 5 .0313 [96.8% CI, 0.2830-1.189];
tTG2 IgA: P 5 .0313 [96.8% CI, 31.45-315.5]; DGP IgA: P 5
.0312 [96.8% CI, 45.40-123.4]; and DGP IgG: P 5 .0313
[96.8%CI, 3.710-85.00]), but according to themanufacturer’s rec-
ommended cutoffs, 5 of 6 serum sampleswere still positive for IgA
against tTG2, 2 of 6 still showed anti-DGP IgA, and 4 of 6
continued to mount anti-DGP IgG (Fig 4, A). By contrast, each
of the 6 patients lost IgA reactivity to rGG1 after a GFD (Fig 4, A).
Using sera from 18 patients with CD on a GFD for cross-
sectional testing (Fig 4, B), we found that each of the 18 patients
had negative results for rGG1-specific IgA, whereas 2 showed IgA
FIG 3. IgA reactivity to rGG1 and gliadin extract (e). A, Sera from patients with CD, patients with IDs, healthy
persons, patients with IgE-associated allergies, and AGA1/EMA2 subjects were tested for IgA reactivity to
rGG1 and gliadin extract (e) by means of ELISA. The results are shown as a scatter plot, and OD values cor-
responding to the amounts of bound antibodies are displayed on the y-axes. The horizontal lines within
groups indicate the median, and the dotted horizontal lines indicate the cutoff values based on the Youden
index (P values between 2 groups are indicated to denote significance). B, Receiver operating characteristic
(ROC) curves comparing IgA reactivity with rGG1 and gliadin extract (e) as CD-specific markers.
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was significant (P5 .0461; 95.32% CI, 0.00200-0.0790). Eight of
18 patients still had positive test results for tTG2-specific IgA, 3 of
18 had positive results for anti-DGP IgA, and 8 of 18 had positive
results for DGP-specific IgG (Fig 4, B).The major IgA-reactive epitope of GG1 is a peptide
in the N-terminal proline- and glutamine-rich
domain II
Peptides 4, 5, 6, 7, and 9 belonging to domain II showed strong
IgA reactivity to serum from patients with active CD. Peptide 4from domain II (Fig 1, boxed in green) was the most strongly and
frequently recognized peptide (Fig 5, A). The sequence of peptide
4 was highly conserved in the GG1 homologue from spelt but less
in barley, whereas the peptide 4–homologous region was either
missing or not conserved in the prolamins from rye, rice, and
oat (Fig 1). In addition to peptide 4, we found IgA reactivity to
peptides 2 and 3 of domain II, peptide 13 of domain III, and
peptide 18 of domain V, but these peptides showed much weaker
reactivity (Fig 5,A). None of the other peptides was recognized by
IgA from patients with CD, and none of the healthy subjects had
peptide-specific or rGG1-specific IgA reactivity. rGG1 exhibited
specific IgA reactivity for all patients with CD (Fig 5, A).
FIG 4. Antibody reactivities of patients with CD on aGFD. Sera obtained from 6 patients with CD ‘‘before and
after’’ a GFD (A) and from 18 patients with CD on a GFD (B)were tested for IgA reactivity to rGG1, tTG2, and
DGP, as well as for IgG against DGP. OD values and units per milliliter corresponding to bound antibody
levels are shown on the y-axes. Cutoff values for each assay are indicated by horizontal dashed lines (P
values between 2 groups are indicated to denote significance).
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FIG 5. Epitope mapping of GG1 using synthetic overlapping peptides. IgA (A) and IgG (B) reactivity of
patients with active CD (n 5 8) and healthy persons (n 5 3) to GG1-derived peptides (Fig 1) or to rGG1
(x-axes) by using ELISA. The results are shown as box plots of OD values for each group, where 50% of
the values are within the boxes, lines within the boxes indicate median values, and open circles and stars
indicate outliers and extremes, respectively.
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serum dilution, the reactions were much weaker than for IgA.
Again, peptide 4 was the most strongly recognized peptide, and
peptides 6, 7, and 13 were also reactive, although to a lower
extent. All patients with CD had IgG reactivity to rGG1, and none
of the healthy subjects had relevant IgG reactivity to any of the
peptides or rGG1 (Fig 5, B).
Testing of the peptides with rabbit anti-rGG1 antibodies
showed that they recognized most of the peptides, although at
varying intensities (see Fig E3 in this article’s Online Repositoryat www.jacionline.org). Rabbit anti–peptide 4 and anti–peptide
18 antibodies showed high specificity with the immunogens.
The preimmune sera showed no reactivity (see Fig E1).rGG1-like proteins can be detected in certain
cereals and are resistant to baking
Using rabbit anti-rGG1 antibodies, we searched for cross-
reactive proteins in several cereals by means of immunoblotting,
and Fig 6, A, shows that proteins of comparable molecular weight
FIG 6. Detection of GG1-like proteins in cereal and bread extracts. Protein extracts from wheat, rye, spelt,
barley, oat, rice, and maize (A) and extracts from the crumb and crust of (I) common bread (I), rolls (II), rye
bread (III), and gluten-free bread (GFB; B) were blotted onto nitrocellulose membrane and probed with
preimmune serum (left panels) or rabbit anti-rGG1 antibodies (right panels). Molecular weights in
kilodaltons are shown on the left margins.
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and, to a lesser degree, in rye and barley. Only weak reactivity
was observed to protein bands of different molecular weights in
oat, rice, and maize, which is also in agreement with the results
frommultiple sequence alignment (Fig 1) and clinical experience
that patients with CD can eat products derived from oat, rice, and
maize.27,28 No reactivity was observed with the corresponding
preimmune serum (Fig 6, A, left panel).
It has been reported that high temperatures induce changes in
the gliadin structure through formation of new hydrophobic and
disulfide bonds29,30 and that such changes cause aggregation of
gliadins and decrease their digestibility.31 Therefore we studied
whether GG1 can be found in processed food and after baking.
For this purpose, we analyzed the presence of GG1 protein inbreadcrumbs and crust protein extracts from 3 different types of
commonly consumed breads (Fig 6, B). Immunoblot analysis
with rabbit anti-rGG1 antibodies indeed shows that an approxi-
mately 35-kDa protein band is present in both the crumb and crust
in each of the tested products but only in trace amounts in gluten-
free bread. Again, no reactivity of the preimmune serum was
observed (Fig 6, B, left panel).rGG1 and its major IgA-reactive epitope are
resistant to gastric digestion
GG1 was first digested with pepsin for 2 hours, and aliquots
were taken at 30, 60, and 120 minutes. After 2 hours of peptic
digestion, the rest of the samples were further digested with
FIG 7. Immunoblot detection of GG1 after peptic and chymotryptic digestion. A, Silver-stained SDS-PAGE
gels of undigested rGG1 (lane a) and rGG1 digested with pepsin for 30 (lane b), 60 (lane c), and 120 (lane d)
minutes. Lanes e to i contain rGG1 samples,which after 120minutes of peptic digestionwere further digested
with chymotrypsin for 30 (e), 60 (f), 120 (g), 240 (h), or 1200 (i) minutes. Molecular weights are indicated as
kilodaltons. B-D, Identically prepared gels were blotted onto nitrocellulose and then probed with rabbit
anti-rGG1 antibodies (right panel) or the corresponding preimmune serum (Pre-Ig; left panel) in Fig 7, B;
with rabbit anti–peptide4antibodies (rightpanel)or thepreimmuneserum (left panel) in Fig7,C; orwith rabbit
anti–peptide 18 antibodies (right panel) or the preimmune serum (left panel) in Fig 7, D.
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240, and 1200 minutes. Silver-stained SDS-PAGE (Fig 7, A)
shows that digestion with pepsin generated fragments of
approximately 23 to approximately 2 kDa (Fig 7, A, lanes b-d).
Subsequent digestion with chymotrypsin further digested the
20-kDa band, generating additional smaller fragments to
approximately 11 kDa (Fig 7, A, lanes e-i). Immunoblot analysis
with rabbit anti-rGG1 antibodies showed that after 2 hours of
digestion with pepsin and 2 hours of digestion with chymotrypsin,
certain immune-reactive rGG1 fragments remained intact (Fig 7,
B, right panel, lanes b-g). Probing the samples with the anti–
peptide 4 antibodies revealed that the region containing peptide
4 was very resistant to pepsin digestion (Fig 7, C, right panel,
lanes b-d). By contrast, the region containing peptide 18, which
was not recognized by IgA antibodies from patients with CD,
was digested almost completely (Fig 7, D, right panel, lanes
b-d). Treatment of pepsin-digested samples with chymotrypsin
resulted in generation of protein fragments, which were still
reactive with anti-rGG1 antibodies (Fig 7, B, lanes e-g), and the
reactivity was lost during very prolonged digestion.
Chymotrypsin-digested samples did not show reactivity with
anti–peptide 4 and anti–peptide 18 antibodies (Fig 7, C and D,
right panel, lanes e-i).DISCUSSION
We cloned, expressed, and purified rGG1, which was specif-
ically recognized by IgA antibodies from 73.01% of patients with
CD, demonstrating that it is a major IgA-reactive wheat antigen.
In pilot tests sensitivity of the rGG1-based IgA testing was lower
when compared with gliadin extract (e)–based testing, but by
using rGG1, a higher specificity of 92.9% was obtained. This
specificity was higher when compared with that of native gliadin
extract (e), which had a specificity of only 75.8%. Thus our results
indicate that rGG1 is a major CD-specific antigen.
Because the only treatment option available for patients with
CD is to be on a lifelong GFD, monitoring the patient’s adherence
to this diet is important. Although in our pilot study we could test
only a limited number of patients before and after a GFD and a
second set of sera after a GFD, our results suggest that IgA
reactivity to rGG1 might be better suited for monitoring GFD
adherence when compared with measuring antibody levels
against tTG2 or DGP. Thus IgA reactivity to rGG1 can be used
as a marker for monitoring GFD adherence in patients with CD.
We next determined the IgA epitopes of GG1 using a set of
synthetic overlapping peptides spanning the GG1 sequence. IgA
antibodies from patients with CD identified mainly peptides (ie,
peptides 4, 5, 6, 7, and 9) in the proline- and glutamine-rich
repetitive region at the N-terminus, of which one peptide (ie,
peptide 4) was most strongly and frequently recognized.
Interestingly, IgG antibodies, although to a weaker extent, were
directed against these peptides, indicating a coevolution of the
antibody response in the IgA and IgG class in patients with CD.
Of note, the sequence motif QPQQPF, which has previously been
identified by means of random phage cloning with sera from
patients with CD, occurs in peptides 4, 5, 6, and 7, and a similar
motif (QPQQPQ) can be found in peptide 9.32
Our assumption that GG1 could be an important CD-specific
antigen is also supported by the fact that it contains a T-cell
epitope, which has been previously mapped with a T-cell clone
that was isolated from the gut of a patient with CD.23,24 This T-cellepitope overlaps with the IgA-reactive peptide 9 (Figs 1 and 2).
The sequence alignment of GG1 with the corresponding
prolamins from other cereals showed that the formerly described
T-cell epitope is well conserved only in spelt but not in rye and
barley, which might explain the selective T-cell recognition
reported earlier.23 By contrast, the rabbit anti-rGG1 antibodies
showed cross-reactivity with those cereals (ie, rye, barley, and
spelt) that are also not well tolerated by patients with CD, whereas
little or no reactivity was observed with oat, rice, and maize,
which can be part of the diet of patients with CD.27,28 These
data suggest that it might be possible to use the rabbit anti-
rGG1 antibodies for screening of various types of processed
food to detect GG1- and GG1-related proteins and for subsequent
food labeling. This assumption is further supported by the finding
that anti-rGG1 antibodies detected GG1 strongly in various
breads, whereas only weak signals were obtained with gluten-
free bread. Using anti-rGG1 antibodies, we also could demon-
strate that GG1 is resistant to baking. This finding might explain
why it can serve as a major CD antigen in baked and processed
foods. Perhaps even more important was the finding that rGG1
was resistant to pepsin and partly to chymotrypsin digestion
because peptide fragments reactive to anti-rGG1 were still
detected after full pepsin digestion and a subsequent 4 hours of
chymotrypsin digestion. Interestingly, the major IgA-reactive
region of rGG1 was particularly resistant because fragments
reactive to the anti–peptide 4 antibodies but not to anti–peptide
18 antibodies were observed after peptic digestion.
In summary, we have cloned and expressed a major
CD-specific wheat antigen. Based on the GG1 sequence and
epitope mapping, it might be possible to develop new forms of
prevention and treatment for CD.
Clinical implications: rGG1 and a synthetic peptide containing
amajor IgA-reactive epitope thereof can be used asmarkers for
CD.
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FIG E1. Schematic representation of GG1. A, Depiction of the domain architecture of GG1. The signal
peptide is followed by a short N-terminal nonrepetitive domain (I), a highly variable Pro- and Gln-rich
repetitive domain (II), a cysteine-rich nonrepetitive domain (III), a Gln-rich region (IV), and the C-terminal
nonrepetitive domain containing 2 conserved cysteine residues (V). B, Sequence of synthetic GG1 peptides.
Displayed are peptide numbers, amino acid sequences, positions of the peptides in the full length GG1, and
their lengths. Asterisks indicate peptides that have not been tested. The coloring of the letters is based on
the domain architecture, as described in Fig E1, A.
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 6
SRINIVASAN ET AL 1618.e1
FIG E2. MALDI-TOF analysis of purified rGG1. The m/z ratio is provided on
the x-axis, and the signal intensity (in arbitrary units) is shown on the y-axis.
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FIG E3. IgG reactivity of preimmune sera (Pre-Ig) and immune sera from rabbits immunized with rGG1,
peptide 4, or peptide 18 of GG1-derived peptides (Fig E1) with GG1-derived peptides or rGG1 (x-axes) as
tested by using ELISA. OD values (y-axis) correspond to the amount of bound antibodies.
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